Redwood Pharma AB (REDW.ST)
Redwood Pharma AB operates in the Biotechnology industry of the Healthcare sector, headquartered in Stockholm, SE. The stock last traded at $1.19, up 0.00% on the session, giving a market capitalisation of $3.1M. Its beta of 0.41 implies it has historically moved less than the broad market.
Redwood Pharma AB focuses on creating pharmaceutical treatments for eye-related conditions, addressing medical needs that currently lack effective solutions. The company's leading product in development is RP101, an eye drop designed to treat severe and persistent dry eye disease, specifically targeting post-menopausal women. They employ IntelliGel, an advanced supramolecular smart drug delivery system, to develop topical formulations for various ophthalmic uses and to deliver treatments directly to the eye's surface. Redwood Pharma AB is based in Stockholm, Sweden.
Redwood Pharma AB is most often compared with the following Healthcare names: